Discovery of chemical profiles for infectious diarrhoea

It is hoped the discovery of these chemical profiles will lead to the development of an electronic device capable of rapid diagnosis at the bedside, saving both time and money.

The study has just been published online in The FASEB Journal. It is the result of a collaboration between Dr Chris Probert, Consultant and Reader in Gastroenterology at Bristol University and Professor Norman Ratcliffe at the University of the West of England.

For a long time it has been known that stools have distinctive and different odours if there is an infection. What the researchers have done is to take this 'knowledge' a step further by analysing the odour of faeces from healthy donors and comparing it with patients with gastrointestional disease to see if precise chemical profiles can be established.

The researchers found that the faeces of patients with ulcerative colitis, Campylobacter jejuni and Clostridium difficile (C. Diff.) all had significantly different chemical compositions.

Dr Chris Probert said: “The discovery of chemical profiles is a major step forward in the diagnosis and treatment of people with gastrointestinal disease. Early treatment of Clostridium difficile means patients have a much better chance of survival and fewer complications. However, at present the average length of time taken to diagnose the condition is eight days. “

The next stage of the academics' research is to develop a prototype rapid diagnosis device able to be operated by healthcare staff at all levels.

Professor Norman Ratcliffe, of UWE's Centre for Research in Analytical, Materials and Sensors Science, said: “There are numerous different kinds of infection that cause diarrhoea and a speedy diagnosis would lead to more appropriate use of antibiotics. A rapid diagnosis device has the potential to save lives and reduce the cost burden to the NHS. Early isolation of infectious patients would reduce hospital outbreaks leading to fewer ward/hospital closures.”

Two of the most common types of infectious diarrhoea are Campylobacter jejuni and Clostridium difficile (C. Diff.). Although less well known than the MRSA superbug, C. Diff. is just as serious, and affects more than 50,000 people each year in England and Wales at a cost to the NHS of around £60 million.

Dr Chris Probert added: “There is a huge potential for a rapid diagnosis device in the UK – 30,000 samples are tested in Bristol alone each year. However, the device could be adapted for use in developing countries where 7,000 children die as a result of diarrhoea every day. Our next aim is to produce a prototype device capable of diagnosing in any healthcare setting.”

“Rapid diagnosis of intestinal illnesses is as useful a contribution to public health as one could imagine,” said Gerald Weissman, M.D., editor-in-chief of the FASEB Journal. “The method developed by Garner et al is not only useful, but also imaginative.”

Last year the team were awarded £353,000 by the Wellcome Trust under their University Translation Award scheme and this study is funded by the grant, which is part of a three-year project.